Company Filing History:
6 out of 647 
6 out of 203 
1 out of 832,843 Years Active: 2002-2022
Title: Joanne Murphy-Ullrich: Innovator in TGF-beta Inhibition
Introduction
Joanne Murphy-Ullrich is a prominent inventor based in Birmingham, AL (US). She has made significant contributions to the field of biomedical research, particularly in the development of compounds that inhibit TGF-beta, a critical pathway in various diseases.
Latest Patents
Murphy-Ullrich holds 8 patents, with her latest innovations focusing on piperazine-2,5-diones and dipeptide analogs as TGF-beta inhibitors. The patent for piperazine-2,5-diones outlines methods for treating cancers, such as multiple myeloma and hematologic malignancies, as well as fibrotic conditions. Similarly, her work on dipeptide analogs emphasizes their potential in cancer treatment and immunotherapy, showcasing her commitment to advancing therapeutic options.
Career Highlights
Throughout her career, Murphy-Ullrich has been associated with reputable organizations, including the UAB Research Foundation and Southern Research Institute. Her work has not only contributed to scientific knowledge but has also paved the way for new treatment methodologies.
Collaborations
Murphy-Ullrich has collaborated with notable colleagues, including Mark J. Suto and Vandana Gupta. These partnerships have enhanced her research efforts and broadened the impact of her innovations.
Conclusion
Joanne Murphy-Ullrich's work in TGF-beta inhibition exemplifies the vital role of inventors in advancing medical science. Her patents and collaborations reflect her dedication to improving treatment options for serious health conditions.